|

Golicitinib combined with Pomadomide Clinical Trials

1 actively recruiting trial

Also known as: Golidocitinib: JAK1 Inhibitor, Pomalidomide: Third-generation Immunomodulatory Drug (IMiD)

Other1 trial

A Phase I/II Study of Golidocitinib Combined with Pomalidomide in R/R PTCL
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.